close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.25 -0.23 (-0.94%)
Official Closing Price Updated: 7:00 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
41 42 Next >
News headline image
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
News headline image
Phio Pharmaceuticals Announces New Chief Financial Officer
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... 
Via Newsfile
Topics Initial Public Offering
News headline image
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July. 
Via MarketBeat
Topics ETFs
News headline image
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
News headline image
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
From Pfizer Inc.
Via Business Wire
News headline image
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
News headline image
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
News headline image
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
Via Investor Brand Network
News headline image
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
From Pfizer Inc.
Via Business Wire
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
Via AB Newswire
News headline image
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
News headline image
3 Stock Giants Analysts Are Bullish On Despite Struggles
Despite recent struggles, PYPL, BABA, and PFE present attractive opportunities with favorable P/Es, high dividend yields, and analyst-predicted upsides. 
Via MarketBeat
News headline image
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
News headline image
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
News headline image
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
News headline image
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
News headline image
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Declares Third-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
News headline image
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
Precision Medicine M&A is Transforming the Future of the Biotech Industry
Via AB Newswire
News headline image
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
From Pfizer Inc.
Via Business Wire
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
News headline image
Novavax Stock’s Recent Surge and Future Potential
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance. 
Via MarketBeat
Topics Economy
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.